These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 28353033)
21. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET. Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598 [TBL] [Abstract][Full Text] [Related]
22. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Yeo KK; Alexandrescu S; Cotter JA; Vogelzang J; Bhave V; Li MM; Ji J; Benhamida JK; Rosenblum MK; Bale TA; Bouvier N; Kaneva K; Rosenberg T; Lim-Fat MJ; Ghosh H; Martinez M; Aguilera D; Smith A; Goldman S; Diamond EL; Gavrilovic I; MacDonald TJ; Wood MD; Nazemi KJ; Truong A; Cluster A; Ligon KL; Cole K; Bi WL; Margol AS; Karajannis MA; Wright KD Neuro Oncol; 2023 Jan; 25(1):199-210. PubMed ID: 35604410 [TBL] [Abstract][Full Text] [Related]
23. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451 [TBL] [Abstract][Full Text] [Related]
24. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism? Singh A; Gurav M; Dhanavade S; Shetty O; Epari S Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849 [TBL] [Abstract][Full Text] [Related]
26. IDH mutations in glioma and acute myeloid leukemia. Dang L; Jin S; Su SM Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206 [TBL] [Abstract][Full Text] [Related]
27. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Dimitrov L; Hong CS; Yang C; Zhuang Z; Heiss JD Int J Med Sci; 2015; 12(3):201-13. PubMed ID: 25678837 [TBL] [Abstract][Full Text] [Related]
28. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534 [TBL] [Abstract][Full Text] [Related]
29. IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy. Uckermann O; Yao W; Juratli TA; Galli R; Leipnitz E; Meinhardt M; Koch E; Schackert G; Steiner G; Kirsch M J Neurooncol; 2018 Sep; 139(2):261-268. PubMed ID: 29761368 [TBL] [Abstract][Full Text] [Related]
30. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Weller M; Wick W; von Deimling A Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161 [TBL] [Abstract][Full Text] [Related]
31. [Advance of molecular subtyping and precise treatment for gliomas]. Hua W; Mao Y Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):63-66. PubMed ID: 28056258 [TBL] [Abstract][Full Text] [Related]
32. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018 [TBL] [Abstract][Full Text] [Related]
33. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222 [TBL] [Abstract][Full Text] [Related]
34. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430 [TBL] [Abstract][Full Text] [Related]
35. Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry. Xu H; Xia YK; Li CJ; Zhang JY; Liu Y; Yi W; Qin ZY; Chen L; Shi ZF; Quan K; Yang ZX; Guan KL; Xiong Y; Ng HK; Ye D; Hua W; Mao Y Lab Invest; 2019 Apr; 99(4):588-598. PubMed ID: 30573870 [TBL] [Abstract][Full Text] [Related]
36. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
37. IDH-mutant gliomas with additional class-defining molecular events. Ahrendsen JT; Torre M; Meredith DM; Hornick JL; Reardon DA; Wen PY; Yeo KK; Malinowski S; Ligon KL; Ramkissoon S; Alexandrescu S Mod Pathol; 2021 Jul; 34(7):1236-1244. PubMed ID: 33772213 [TBL] [Abstract][Full Text] [Related]
38. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925 [TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach. Sipayya V; Sharma I; Sharma KC; Singh A J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281 [TBL] [Abstract][Full Text] [Related]
40. A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas. Pang B; Durso MB; Hamilton RL; Nikiforova MN Diagn Mol Pathol; 2013 Mar; 22(1):28-34. PubMed ID: 23370430 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]